Key result
Formulary Monograph Service provides monthly evaluated drug monographs to guide Pharmacy and Therapeutics Committee decisions.
Key points are not available for this paper at this time.
Design
Other
Answers are grounded in this paper and cite their sources.
Supports P&T review of late-phase agents; extends evidence synthesis for hospital formulary decisions.
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The March 2003 monograph topics are adalimumab, eletriptan, cyclosporine ophthalmic emulsion, montelukast for allergic rhinitis, and icodextrin peritoneal dialysis solution. The DUE is on adalimumab.
No takes yet. Share an insight, caveat, or question.
Cada et al. (2003) studied this question. The Formulary Monograph Service provides monthly well-documented monographs and drug utilization evaluations for Pharmacy and Therapeutics Committees on newly released and late Phase III drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: